Raymond James raised the firm’s price target on Disc Medicine (IRON) to $108 from $89 and keeps a Strong Buy rating on the shares. The announcement that bitopertin is among the first cohort of drugs to receive the FDA Commissioner’s National Priority Voucher is highly positive, potentially accelerating the bitopertin launch in EPP by more than a quarter, and further increasing the firm’s confidence in the prospects for accelerated approval, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- 3 Best Stocks to Buy Now, 10/17/2025, According to Top Analysts
- Disc Medicine price target raised to $110 from $90 at Wedbush
- Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch
- Disc Medicine receives CNPV from FDA for Bitopertin
- Disc Medicine Board Member Mona Ashiya Resigns